Health Care/Hospital
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...
2024-01-08 07:00
1446
Nuvilab Innovates Inpatient Nutrition with Food AI at Alexandra Hospital Singapore
SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital. This solution uses an AI Food Scanner to scan each patient's meal tray and...
2024-01-05 22:46
2751
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
2024-01-05 21:00
5694
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...
2024-01-05 19:44
2996
Grant of Restricted Share Units to Mr. Xing Jin
BEIJING, Jan. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the Compensation Committe...
2024-01-05 19:00
6132
Innovations in China's Greater Bay Area: Global Pitch Competition for Startups Announces Winners
SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- Thousands of investors, startups, and industry enthusiasts packed the house and tuned in as the 2023 PHBS-CJBS Global Pitch Competition wrapped up. The spectacular grand final event took place in December, revealing the year's winners and other major ...
2024-01-05 18:23
5602
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...
2024-01-05 16:00
2507
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...
2024-01-05 14:35
1794
Leading New Trends & Stimulating New Vitality, HNC Shenzhen 2023 Came to a Satisfactory Close. See You in Shanghai in 2024.
SHENZHEN, China, Jan. 4, 2024 /PRNewswire/ -- From December 14th to 16th, 2023, the three-day"Healthplex Expo, Natural & Nutraceutical Products Shenzhen 2023" (HNC Shenzhen) came to a successful conclusion at the Shenzhen World Exhibition & Convention Center. Co-organized by CCCMHPIE and Sinoexp...
2024-01-05 10:10
2005
Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice
As the leading percussive patent owner and the driving force behind many of today's wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. LOS ANGELES, Jan. 5, 2024 /PRNewswire/ -- Therabody, the leader in tech wellness and...
2024-01-05 06:33
2445
Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences
Greenway Health™ (Greenway®) offers groundbreaking client-centric electronic health record (EHR) and practice management software that streamline workflows and improve patient outcomes through a unique blend of in-depth insights and cutting-edge technology. SAN ANTONIO, Jan. 5, 2024 /PRNewswire/...
2024-01-05 04:30
2774
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...
2024-01-05 00:19
2514
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...
2024-01-04 21:40
2544
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
* Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors * Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targetingCDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc...
2024-01-04 21:11
1653
Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiova...
2024-01-04 21:05
1716
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...
2024-01-04 21:02
1732
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...
2024-01-04 17:37
4570
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference inSan Francisco, USA. The forum, themed " Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapi...
2024-01-04 16:55
1670
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...
2024-01-04 12:40
1621
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference inSan Francisco, CA (US). The pre...
2024-01-04 06:20
1909
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 314 media titles]
2024-12-02 12:06
AC Health makes critical HIV care more accessible to Filipinos with USAID support
[Picked up by 300 media titles]
2024-12-03 16:11
ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 299 media titles]
2024-11-28 17:24Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 289 media titles]
2024-11-29 20:33
Hong Kong Airlines Resumes Vancouver Service Offering Twice-weekly direct flights from 18 January 2025
[Picked up by 287 media titles]
2024-12-02 20:01
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
9953
China's spicy hotpot sets its sights on global market
2024-11-29 21:36
4334
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
2024-11-30 09:00
4310